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ABSTRACT: A convergent synthesis of fluvirucinin B1 from acid ent-6a and nitrile ent-9, involving an organocopper coupling, a 
stereoselective allylation, a ring-closing metathesis reaction, and a stereoselective hydrogenation as the key steps, is reported. The 
starting building blocks have been prepared in a straightforward manner from a common phenylglycinol-derived lactam 1. An 
unprecedented regioselective oxidation of phenylglycinol-derived secondary amines 5 to carboxylic acids 6 has been developed.  
Fluvirucins  are  14-membered  macrocyclic  lactams isolat-
ed1–3 from the fermentation broth of actinomycete strains. 
They are glycosides characterized by the presence of an ami-
nosugar moiety (L-mycosamine, its 4-epimer, or an N-
substituted derivative) attached at the C-3 or C-9 positions of 
the core lactam nucleus through a hydroxy group. They also 
incorporate a methyl or ethyl substituent at the C-2 (1S-
hydroxyethyl in fluvirucin A2), C-6 (absent in some members), 
and C-10 positions (Figure 1). Fluvirucins possess important 
and varied biological activities, such as antifungal,1  antibi-
otic,2  antiviral,2   and anthelmintic.3 In particular, fluvirucin B1 
(Sch 38516) exhibits potent antifungal1a,c and anti-influenza 
virus2a activities,4 the latter partially retained in the corre-
sponding aglycon fluvirucinin B1.2b 
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Figure 1. Representative fluvirucins. 
 
Although only one total synthesis of a fluvirucin has been 
reported,5 the synthesis of the macrolactam aglycons of fluvir-
ucins, known as fluvirucinins, has received more attention.6-10 
A key point in the synthesis of fluvirucinins is the stereocon-
trolled assembly of the stereocenters on the macrocyclic ring. 
Taking into account that all fluvirucinins B possess the same 
substitution and stereochemical patterns at the C-2 (R-Et), C-9 
(S-OH), and C-10 (R-Et) positions, differing only in the C-6 
substituent   (none   in  fluvirucinin  B0,  S-Me in B1, S-Et in  
 
Scheme 1. Unified Synthetic Strategy to Fluvirucinins B 
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 B2-5), we envisaged a unified synthetic strategy to these macro-
lactams in which the C-2  and C-10 ethyl substituents would 
come from a common enantiopure amino diol 2, easily acces-
sible by reductive opening of oxazolopiperidone lactam 1.11 
Scheme 1 outlines our synthetic plan. 
Amino diol 2 would be converted to a 5-hydroxypentanoic 
acid derivative A by oxidative removal of the phenylglycinol 
moiety and then to the C1–C6 fragment of fluvirucinins B by 
copper-catalyzed coupling of the corresponding iodide with an 
appropriately substituted (R = H, Me or Et) alkenyl Grignard 
reagent. In turn, the secondary amino group of amino diol 2 
would be oxidized to a cyano group, and the resulting 5-
hydroxypentanenitrile B would be converted to the C7–N 
fragment of fluvirucinins B after the incorporation of the C-9 
stereogenic center by a stereoselective allylation of an alde-
hyde. Linkage of the two fragments by an amidation reaction, 
followed by a ring-closing metathesis and stereoselective 
hydrogenation of the resultant alkene would complete the 
synthesis of the target fluvirucinins B. The success of our 
synthetic plan would rely on the development of efficient 
procedures for the oxidative removal of the phenylglycinol 
moiety present in amino diol 2 to afford 5-hydroxypentanoic 
acid and 5-hydroxypentanenitrile derivatives.  
The conversion of a secondary amine to a carboxylic acid is 
a challenging, unprecedented transformation. Taking into 
account that primary amines are oxidized to nitro derivatives 
by treatment with m-chloroperbenzoic acid,12 we decided to 
study this oxidation using a set of phenylglycinol-derived 
secondary amines structurally related to 2.  
To our delight, treatment of the O-protected amino diols 5a–
d with an excess of m-CPBA (4.2 equiv) in refluxing CH2Cl2 
directly afforded the corresponding carboxylic acids 6a–d, 
bearing a variety of substituents (ethyl, benzyl, isopropy-
lidenedioxy) in good yields (Scheme 2). Considering that 
amino diols 4 are available with virtually any type of substitu-
tion pattern,11 the above oxidative procedure opens a general 
synthetic entry to enantiopure 5-hydroxypentanoic acid deriva-
tives. 
The formation of carboxylic acids 6 can be accounted for by 
considering the generation of the nonconjugated nitrones 713 
and their m-CPBA-promoted oxidative cleavage14 with subse-
quent oxidation of the resulting aldehyde. The oxidative 
cleavage also produces a nitroso derivative, which was isolat-
ed as the corresponding nitroso dimer 8 (Scheme 3).  
 
Scheme 2. Oxidative Removal of the Chiral Inductor. Access 
to Enantiopure O-Protected 5-Hydroxypentanoic Acids 
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In support of this mechanism, nitrone 7e, prepared by 
Na2WO4/hydrogen peroxide–urea oxidation13b of the simple 
secondary amine 5e, was converted to hydroxypentanoic acid 
derivative 6e (45% from 5e) and dimer 8 by treatment with m-
CPBA (2.5 equiv). 
 
Scheme 3. Proposed Mechanism for the m-CPBA-Promoted 
Oxidation of Secondary Amines 5 
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On the other hand, the generation of a 5-hydroxy-
pentanenitrile by oxidative cleavage of the phenylglycinol 
moiety of the starting O-protected amino diol was successfully 
accomplished in a single step using molecular iodine in aque-
ous ammonia.15  In this way, secondary amine 5a was convert-
ed to nitrile 9 in 71% yield (Scheme 4). 
This transformation involves the initial generation of an 
imine and its reaction with ammonia to form an aminal, which 
decomposes to a primary amine and an imine. Subsequent 
oxidation and hydrolytic steps lead to the nitrile and (tert-
butyldiphenylsilyloxy)methyl phenyl ketone, regardless of the 
regioselectivity of the initial oxidation.  
 
Scheme 4. Oxidation of Secondary Amine 5a to Nitrile 9 
 
NH
C6H5 I2
 
(8
 equiv)
NH3
, THF
60
 ºC
971%5a
OR
R=
 
TBDPS
RO
C
TBDPSO
N
 
 
Having developed straightforward procedures for the con-
version of secondary amines 5 to functionalized carboxylic 
acids 6 and nitrile 9, to evaluate the feasibility of the unified 
strategy outlined in Scheme 1, we undertook the synthesis of 
fluvirucinin B1. To achieve the required 2R and 10R configu-
ration characteristic of fluvirucinins B, we started from the 
(S)-phenylglycinol-derived secondary amine ent-4a (= 2), 
which was converted, as in the above (R)-phenylglycinol 
series, to hydroxy acid ent-6a (A; Prot = TBDPS) and hydroxy 
nitrile ent-9 (B; Prot = TBDPS).  
Scheme 5 outlines the synthesis of fluvirucinin B1. The C1–
C6 fragment (compound 12) was prepared from carboxylic 
acid ent-6a, which was converted, via an alcohol, to iodide 10.  
 Scheme 5. Total Synthesis of Fluvirucinin B1a 
N
N
Si
p-C6H4Br
Cl
p-C6H4Br
TBDPSO
COOH
ent-6a
TBDPSO I HO
O
10 12
1.
 
BH3
2.
 
Ph3P
, I2    
imidazole
1.
 
TBAF
2.
 
(COCl)2
, DMSO    
then
 
NaClO2
TBDPSO
CN
ent-9
H
CN
13
O
CN
OH
14
OTBDMS
15
NH2
1.
 
TBAF
2.
 
(COCl)2    
DMSO
1.TBDMSCl
2.
 
LiAlH4
85% 67%
81% 59%
Sc(OTf)3
68%
EDCl
HOBT
H-G
 
II
 cat.
1.
 
H2
, Pd/C
2.
 
HCl,
 
EtOH
79%
78%
CuI TBDPSO
MgBr
 
Fluvirucinin
 
B1
R
16
6
7
13
R
R
17
6
9
102 R
R
R
S
HN
O
OTBDMS
1
11
1
R
5
R
5
6 6
1
9
13
HN
O
OTBDMS
HN
Me
O
OH
7
8
9
R
R 13
7
84%
89%
Me
 
a The carbon numbering of the intermediates corresponds to that of fluvirucinin B1 
 
A subsequent cross-coupling with 2-propenylmagnesium 
bromide in the presence of a catalytic amount of CuI16 (bond 
formed C5–C6) provided the protected alcohol 11, which was 
desilylated and oxidized to carboxylic acid 12 (23% overall 
yield from 1). 
On the other hand, after the protected hydroxy nitrile ent-9 
was converted to aldehyde 13, a stereoselective allylation 
using the (S,S)-Leighton reagent17 installed the C-9 stereogenic 
center to give homoallylic syn alcohol 1418 (bond formed C8–
C9). Protection of the hydroxy group of 14, followed by reduc-
tion of the cyano group, afforded amine 15 (the C7-N fragment 
of fluvirucinins B) in 21% overall yield from 1. 
Coupling of the two fragments, carboxylic acid 12 and 
amine 15, took place in excellent yield to give amide 16. A 
subsequent ring-closing metathesis reaction (bond formed C6–
C7), followed by stereoselective catalytic hydrogenation of the 
resulting 1.2:1 mixture of trisubstituted olefins 17, generated 
the  C-6  stereocenter  of  the macrocycle,19  leading  to  the  
O-protected fluvirucinin derivative 18. The NMR data of our 
silyl derivative 18 matched those reported in the literature,5b,9b  
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Figure 2. X-ray crystal structure of the fluvirucinin B1 precursor 
18. 
and its mp and absolute rotation were consistent with those 
previously reported.9b Additionally, the absolute configuration 
of 18 was unambiguously established by X-ray crystallog-
raphyic  analysis20  (Figure 2). A final removal of the silyl 
protecting group completed the synthesis of fluvirucinin B1, 
whose NMR data and [α] value are reported for the first time 
(see the Supporting Information). 
The convergent enantioselective synthesis of fluvirucinin B1 
herein reported consists of 12 linear synthetic steps from phe-
nylglycinol-derived lactam 121 in the longest linear sequence. 
The overall yield was 11%, which compares advantageously 
with previous syntheses9 of this aglycon. The synthesis also 
features an unprecedented oxidation of phenylglycinol-derived 
secondary amines 5 to diversely substituted enantiopure 5-
hydroxypentanoic acid derivatives 6. By using an appropriate 
alkenyl Grignard reagent in the assembly of the C1–C6 frag-
ment, the strategy we have developed could be applied to the 
synthesis of fluvirucinins B0 and B2–5.  
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